GlassScriptPhysician profile
Nausheen Ahmed
NPI 1750519856
$60,768.15
in general payments reported to CMS, 2019-2025
22 companies · $36K in 2025
The $36K reported for 2025 was more than what 91% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $234 · 2022: $262 · 2023: $2,951 · 2024: $21K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Honoraria: $11K · Food and Beverage: $2,949 · Travel and Lodging: $2,327 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,910.00 |
| Honoraria | $10,500.00 |
| Food and Beverage | $2,948.63 |
| Travel and Lodging | $2,327.12 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $26,871.35 | 2019-2025 | Yescarta |
| Adc Therapeutics America, INC. | $11,555.73 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,529.41 | 2023-2025 | Abecma, Opdivo |
| Abbvie INC. | $3,071.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,870.00 | 2025 | Calquence |
| Legend Biotech USA INC. | $2,462.50 | 2024 | Carvykti |
| Invivyd INC | $2,100.00 | 2024 | Pemgarda |
| Genentech USA, INC. | $336.55 | 2019-2025 | |
| Janssen Biotech, INC. | $267.64 | 2025 | Carvykti, Tecvayli, Talvey |
| Genentech, INC. | $248.76 | 2022-2023 | Lunsumio |
| National Marrow Donor Program | $214.51 | 2024 | |
| Celgene Corporation | $196.93 | 2019-2025 | Breyanzi |
| Genzyme Corporation | $195.37 | 2019-2023 | |
| Syndax Pharmaceuticals, INC. | $145.50 | 2025 | |
| Janssen Scientific Affairs, LLC | $139.36 | 2022-2024 | Darzalex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $118.01 | 2020 | |
| Genmab U.S., INC. | $111.11 | 2024 | Epkinly |
| Merck Sharp & Dohme LLC | $100.24 | 2019 | |
| Lilly USA, LLC | $100.00 | 2019 | |
| Incyte Corporation | $91.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.00 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nausheen Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.